GSK licenses Vectura’s inhalation tech for $32M

GlaxoSmithKline is paying UK-based Vectura group $31.8 million dollars to license Vectura's dry powder drug formulation patents in relation to two late stage development compounds in GSK's respiratory drug pipeline. The drugmaker gets will receive up to £20 million ($31.8 million) in up-front and milestone payments, and Vectura could also earn up to £13 million in royalties on products resulting from use of its patents. According to Dow Jones the patents are for GSK642444...

Vectura unveils clinical development lineup, talks up pact potential

The UK's Vectura Group stirred up some excitement today as it unveiled a lineup of three new development programs headed to the clinic and talked up its chances of signing a collaborator to develop VR315--a generic asthma drug--for the U.S. market. Vectura CEO Chris Blackwell told Dow Jones that he's had a number of queries about a U.S. deal for VR315, widely seen as a generic competitor to Glaxo's Advair. Sandoz, a division of Novartis, returned its U.S. rights to the drug earlier this year...